

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 6185)

INSIDE INFORMATION

**RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS
TYPE 5 VECTOR) RECEIVED MILITARY SPECIALLY-NEEDED DRUG
APPROVAL**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company is pleased to announce that, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (the “**Ad5-nCoV**”), a vaccine jointly developed by the Company and Beijing Institute of Biotechnology, Academy of Military Medical Sciences, received Military Specially-needed Drug Approval (軍隊特需藥品批件) with a valid period for one year from Health Bureau of the Logistics Support Department of the Central Military Commission (中央軍委後勤保障部衛生局) (the “**Logistics Support Department**”) on June 25, 2020.

The phase I and phase II clinical trials of the Ad5-nCoV have been conducted in China and the phase II clinical trial was unblinded on June 11, 2020. Data of clinical trials showed good safety profile and high levels of humoral and cellular immune response. The overall clinical results indicate that the Ad5-nCoV has potential to prevent diseases caused by SARS-CoV-2.

According to “Measures of the Chinese People’s Liberation Army for Implementation of the Drug Administration Law of the People’s Republic of China” (《中國人民解放軍實施〈中華人民共和國藥品管理法〉辦法》), the Ad5-nCoV is currently limited to military use only and its use cannot be expanded to a broader vaccination range without the approval of the Logistics Support Department.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: We cannot guarantee that we will ultimately commercialize the Ad5-nCoV successfully. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, June 29, 2020

As at the date of this announcement, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.